Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

Rowinsky EK, Beeram M, Hammond LA, Schwartz G, De Bono J, Forouzesh B, Chu Q, Latz JE, Hong S, John W, Nguyen B.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):532-9.

2.

Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.

Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.

Clin Cancer Res. 2009 Jan 1;15(1):382-9. doi: 10.1158/1078-0432.CCR-08-0128.

3.

Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.

Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M, Forouzesh B, de Bono J, Tolcher AW, Patnaik A, Monroe P, Wood L, Schneck KB, Clark R, Rowinsky EK.

Clin Cancer Res. 2007 May 1;13(9):2675-83.

4.

Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.

Misset JL, Gamelin E, Campone M, Delaloge S, Latz JE, Bozec L, Fumoleau P.

Ann Oncol. 2004 Jul;15(7):1123-9.

PMID:
15205208
5.

Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.

Hochster H, Kettner E, Kroning H, Becker K, Lordick F, Ramanathan RK, Macdonald J, Hong S, John W, Schmoll HJ.

Clin Colorectal Cancer. 2005 Nov;5(4):257-62.

PMID:
16356302
6.

Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.

Yuan Y, Cohen DJ, Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS.

Cancer Chemother Pharmacol. 2011 Aug;68(2):371-8. doi: 10.1007/s00280-010-1493-8. Epub 2010 Oct 27.

PMID:
20978761
7.

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.

Camidge DR, Blais N, Jonker DJ, Soulières D, Doebele RC, Ruiz-Garcia A, Thall A, Zhang K, Laurie SA, Chao RC, Chow LQ.

Cancer Chemother Pharmacol. 2013 Feb;71(2):307-19. doi: 10.1007/s00280-012-2008-6. Epub 2012 Oct 30.

PMID:
23108697
8.

A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.

Clarke SJ, Boyer MJ, Millward M, Underhill C, Moylan E, Yip D, White S, Childs A, Beale P, Latz J, Suri A, Iglesias JL.

Lung Cancer. 2005 Sep;49(3):401-12.

PMID:
15923057
9.

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.

Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao RC, Camidge DR.

Cancer Chemother Pharmacol. 2012 Mar;69(3):709-22. doi: 10.1007/s00280-011-1755-0. Epub 2011 Oct 12.

10.

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH.

J Clin Oncol. 2006 Feb 1;24(4):552-62. Epub 2006 Jan 3.

PMID:
16391300
11.

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.

Infante JR, Novello S, Ma WW, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, Ottesen LH, Burris HA 3rd, Adjei AA.

Invest New Drugs. 2013 Aug;31(4):927-36. doi: 10.1007/s10637-012-9900-0. Epub 2012 Nov 22.

PMID:
23179337
12.

A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.

Hensley ML, Larkin J, Fury M, Gerst S, Tai DF, Sabbatini P, Konner J, Orlando M, Goss TL, Aghajanian CA.

Clin Cancer Res. 2008 Oct 1;14(19):6310-6. doi: 10.1158/1078-0432.CCR-08-0338.

13.

A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.

Dittrich C, Petruzelka L, Vodvarka P, Gneist M, Janku F, Kysela T, Melemed A, Latz J, Simms L, Krejcy K.

Clin Cancer Res. 2006 Dec 1;12(23):7071-8.

14.

Pemetrexed in advanced colorectal cancer.

Louvet C, de Gramont A.

Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):56-62. Review.

15.

A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.

Underhill C, Goldstein D, Gorbounova VA, Biakhov MY, Bazin IS, Granov DA, Hossain AM, Blatter J, Kaiser C, Ma D.

Oncology. 2007;73(1-2):9-20. doi: 10.1159/000120626. Epub 2008 Mar 11.

PMID:
18334829
16.

Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.

Levy AS, Meyers PA, Wexler LH, Jakacki R, Angiolillo A, Ringuette SN, Cohen MB, Gorlick R.

Cancer. 2009 Jan 1;115(1):207-16. doi: 10.1002/cncr.23992.

17.

A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.

Kalykaki A, Vamvakas L, Agelaki S, Kalbakis K, Vardakis N, Sfakiotaki G, Ignatiadis M, Saridaki Z, Karampeazis A, Mavroudis D, Georgoulias V.

Oncology. 2006;71(3-4):197-203. Epub 2007 Jul 19. Erratum in: Oncology. 2007;73(5-6):406. Karabeazis, A [corrected to Karampeazis, A].

PMID:
17641541
18.

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.

Blais N, Camidge DR, Jonker DJ, Soulières D, Laurie SA, Diab SG, Ruiz-Garcia A, Thall A, Zhang K, Chao RC, Chow LQ.

Invest New Drugs. 2013 Dec;31(6):1487-98. doi: 10.1007/s10637-013-0010-4. Epub 2013 Aug 22.

19.

Phase I trials of pemetrexed.

Fossella FV, Gatzemeier U.

Semin Oncol. 2002 Apr;29(2 Suppl 5):8-16. Review.

PMID:
12023787
20.

Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.

Thödtmann R, Depenbrock H, Dumez H, Blatter J, Johnson RD, van Oosterom A, Hanauske AR.

J Clin Oncol. 1999 Oct;17(10):3009-16.

PMID:
10506594

Supplemental Content

Support Center